We are international
Donate
TEXT SIZE   

ask_dr_durie_banner

 

Have a question? Submit it to AskDrDurie@myeloma.org!
 

facebook
googleplus
twitter
youtube


IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org! For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org.

Our archives are brimming with useful information directed at - and asked by - patients, caregivers, and other interested parties... so please watch the episodes below, and share them as much as possible so that others may benefit!


 

 

 

#Ask Dr. Durie
    next      view all

08.25.16   What is iStopMM?

In this week’s video, Dr. Brian Durie shares the objectives and process for the new iStopMM project.

BOTTOM LINE: 

The iStopMM project has the potential to cure or prevent myeloma for all of Iceland.


08.18.16   Should I change treatment regimens if my IgG myeloma protein has spiked?

In this week’s video, Dr. Durie addresses a concerned patient’s question about lab test results. 

BOTTOM LINE:

If test results seem inaccurate, get them double-checked.


08.11.16   Should a patient in long-term remission with light-chain levels increasing, be treated?

In this week’s video, Dr. Brian Durie recommends how a patient should be monitored if his light chain level is increasing.

BOTTOM LINE:

Assess the myeloma status before making radical treatment changes.


08.04.16   What should be done to carefully monitor myeloma in the remission phase?

In this week’s video, Dr. Durie addresses a patient’s concerns about different recommendations she has received about monitoring her disease.

BOTTOM LINE:

Patients in remission must have their myeloma monitored regularly and see their GP or internist.

 


07.28.16   How important is the new IMWG response criteria, which includes the use of minimal residual disease testing?

In this week’s video, Dr. Brian Durie explains why MRD testing is important for assessing the results of clinical trials, but is not yet ready for the clinic.

BOTTOM LINE:

In clinical trials, the new criteria are essential to assess new drug combination therapies.


07.21.16   Even though the kappa level is normal, the lambda level—the other normal light-chain—why is it also low?

In this video, Dr. Durie discusses why slight reductions in lambda levels in MM patients are not necessarily cause for alarm.

BOTTOM LINE:

Because the kappa, the myeloma light chain, is still in the normal range, the disease is in remission.


06.16.16   What is the difference between high-risk smoldering myeloma and high-risk myeloma?

In this week’s video, Dr. Brian Durie explains the meaning of the term “risk,” as it relates to myeloma.

BOTTOM LINE: 

The use of the word “risk” in myeloma staging can be confusing.


06.09.16   What is the value of ASCT if my myeloma protein level is already zero?

In this video, Dr. Brian Durie discusses how to treat myeloma, even if the myeloma protein level is zero.

The BOTTOM LINE:

Additional treatment at low levels of myeloma does have benefit.


06.02.16   What are the game-changing drugs for myeloma right now?

In this video, Dr. Durie sheds light on two or three new agents that may be effective to optimally treat myeloma.

BOTTOM LINE:

Many new therapies could be game-changers, but it will take time to know which work best.                                                        


05.26.16   Is it reasonable to take Zometa for longer than two years?

In this week’s video, Dr. Durie discusses how to safely use the bisphosphonate Zometa to control myeloma bone disease.

BOTTOM LINE:

Discontinue Zometa after two years unless bone disease is a major concern.


    next      view all